Blockchain Registration Transaction Record

Oncotelic Highlighted for Breakthrough Nose-to-Brain Drug Delivery Platform

Oncotelic Therapeutics (OTLC) featured in BioMedWire editorial for its intranasal nose-to-brain platform overcoming the blood-brain barrier, targeting neurological diseases and biodefense. Learn more about this CNS drug delivery breakthrough.

This news matters because Oncotelic's intranasal delivery platform could revolutionize treatment for neurological conditions by bypassing the blood-brain barrier, enabling faster and more targeted therapies. For patients with brain cancers, Alzheimer's, or other CNS disorders, this technology holds promise for improved outcomes and reduced side effects. Investors should watch as the company advances its pipeline, potentially capturing a significant share of the growing CNS drug delivery market.